BridgeMD
New treatment option for Hypoxic Ischemic Encephalopathy of Newborn
Official title Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
ClinicalTrials.gov ID: NCT06522581
What this study is testing
What is Citicoline Sodium?
Citicoline Sodium is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for hypoxic ischemic encephalopathy of newborn.
Also referred to as placebo.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Hypoxic ischemic encephalopathy is an acute or subacute brain injury, due to asphyxia in neonates, leading to mortality and long-term morbidity. Its prevalence varies across regions, with developed countries reporting rates of 1.5 per 1000 live births, while developing nations experience a wider range from 2.3 to 26.5 per 1000 live births.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 30
You may be able to join if
- all indoor newborn babies with HIE II and III
- who have not received therapeutic hypothermia
You likely can't join if
- grade I HIE
- Babies on TH
- babies whose parents do not give consent for inclusion in study
- babies with major congential malformations -
The study team makes the final eligibility decision.
Where it's taking place
- Rawalpindi, Pakistan
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 day to 30 days. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rawalpindi, Pakistan. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.